What is he best known for?
The fields of study he is best known for:
His primary scientific interests are in Cell biology, Megakaryocyte, Molecular biology, Immunology and Progenitor cell.
His research in Cell biology is mostly concerned with Signal transduction.
Najet Debili studied Megakaryocyte and Platelet that intersect with Immunogold labelling, Immunoelectron microscopy, Cancer research and Fibrinogen.
His Molecular biology research is multidisciplinary, relying on both Cell culture, Receptor and Gene expression, In situ hybridization.
His research integrates issues of Wiskott–Aldrich syndrome protein, Cdc42 GTP-Binding Protein and Thrombopoiesis in his study of Immunology.
His Progenitor cell research is multidisciplinary, incorporating elements of CD34, Haematopoiesis, Cellular differentiation and Polycythemia vera.
His most cited work include:
- c-Mpl ligand is a humoral regulator of megakaryocytopoiesis (618 citations)
- AIF deficiency compromises oxidative phosphorylation (519 citations)
- Platelet formation is the consequence of caspase activation within megakaryocytes (291 citations)
What are the main themes of his work throughout his whole career to date?
Cell biology, Megakaryocyte, Molecular biology, Haematopoiesis and Immunology are his primary areas of study.
Najet Debili interconnects Actin cytoskeleton, Cytoskeleton and Cellular differentiation in the investigation of issues within Cell biology.
Najet Debili has included themes like Platelet, Internal medicine and Thrombopoietin in his Megakaryocyte study.
His work carried out in the field of Molecular biology brings together such families of science as Cancer research, Gene expression, Mutation, Receptor and RUNX1.
His Haematopoiesis study incorporates themes from Progenitor cell, Embryonic stem cell and Cytokine.
His work in the fields of Immunology, such as Bone marrow, overlaps with other areas such as Interleukin 3.
He most often published in these fields:
- Cell biology (66.86%)
- Megakaryocyte (57.56%)
- Molecular biology (49.42%)
What were the highlights of his more recent work (between 2013-2021)?
- Cell biology (66.86%)
- Molecular biology (49.42%)
- RHOA (22.09%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Cell biology, Molecular biology, RHOA, Megakaryocyte and Cancer research.
His studies in Cell biology integrate themes in fields like Gene knockdown, Cytoskeleton and Dynamin.
His Molecular biology study integrates concerns from other disciplines, such as Mutation, Thrombopoietin receptor, Haematopoiesis and Calreticulin.
His RHOA study combines topics in areas such as Protein tyrosine phosphatase, Protein kinase A, Phosphorylation, CDC42 and Actin cytoskeleton.
The study incorporates disciplines such as Thrombopoietin, Immunology and Polyploid in addition to Megakaryocyte.
His study in Cancer research is interdisciplinary in nature, drawing from both Leukemia and RUNX1.
Between 2013 and 2021, his most popular works were:
- Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation (105 citations)
- Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation (105 citations)
- Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. (89 citations)
In his most recent research, the most cited papers focused on:
Najet Debili mostly deals with Molecular biology, Mutation, Cancer research, Leukemia and RUNX1.
His Molecular biology study combines topics from a wide range of disciplines, such as Missense mutation, Induced pluripotent stem cell, Essential thrombocythemia, Thrombopoietin and Cytoskeleton organization.
In general Induced pluripotent stem cell, his work in Human embryonic stem cell line is often linked to Dominant-Negative Mutation linking many areas of study.
His Essential thrombocythemia research is classified as research in Immunology.
His Thrombopoietin research integrates issues from FLI1, Transcription factor, Friend leukemia and MAPK/ERK pathway.
Najet Debili combines subjects such as Exome sequencing, Germline mutation, Filamin, Thrombocytopathy and Platelet activation with his study of Cytoskeleton organization.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
